ECCMID18: Piperacillin-tazobactam should be avoided for bloodstream infections caused by ceftriaxone-resistant E. coli and K. pneumoniae

The antibiotic combination treatment piperacillin-tazobactam has been demonstrated to be significantly less effective than meropenem in treating potentially fatal blood infections caused by ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae. These results, from the MERINO trial, were presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID; 21–24 April, Madrid, Spain) today.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.

Antibiotics Antimicrobial Resistance Clinical Trial Treatments